Solving the Capacity Crisis for Viral Vector Manufacturing
Solving the Capacity Crisis for Viral Vector Manufacturing
Viral vectors for gene therapy have shown tremendous clinical promise which has spurred a huge increase in demand for manufacturing space, resulting in a capacity crisis. This is currently delaying the commercialization of these gene therapies for which time to market is critical.
Integrated solutions for viral vectors designed within modular cleanroom facilities streamline manufacturing and reduce time to market. Pall Biotech and G-CON manufacturing have partnered to design and deploy an integrated manufacturing solution to address the current capacity constraints for viral vector manufacturing.
Participants will learn:
- The manufacturing challenges facing the viral vector industry
- The advantages of an integrated manufacturing solution
- How to develop and deploy a new manufacturing facility in 10 months within a modular cleanroom
Moderator
Clive Glover
Director, Cell & Gene Therapy
Pall Biotech
Presenters
Jeremy Rautenbach
Global Product Manager, Integrated Solutions
Pall Biotech
Joseph Rininger
Director, Cell & Gene Therapy
Latham BioPharm Group
Peter Makowensky
Director, Sales Engineering
G-CON Manufacturing
Maximize Speed to Market Flexibility of Single-Use for Gene Therapy Manufacturing
Listen to Podcast Today
Biotech | Pall Corporation 웨비나 시리즈
¡Todo sobre los ensayos de validaciones para cumplir con los máximos estándares regulatorios!
Hablaremos sobre puntos cruciales de los servicios de validación, incluyendo:
1. Necesidad de validación
2. Cómo se realizan los ensayos de validación
3. Análisis de riesgo: re uso de filtros y toma de decisión en ensayos a realizar
4. Servicio de Validación Pall: documentación requerida para iniciar una cotización
¡No pierdas esta segunda oportunidad!